Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low – Here’s Why

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) reached a new 52-week low on Wednesday . The company traded as low as $5.87 and last traded at $5.94, with a volume of 125877 shares. The stock had previously closed at $6.06.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GYRE shares. Weiss Ratings cut shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Zacks Research cut shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Finally, Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Gyre Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Trading Down 3.0%

The business’s fifty day moving average price is $7.11 and its 200 day moving average price is $7.56. The firm has a market capitalization of $556.95 million, a price-to-earnings ratio of -63.77 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The business had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. As a group, sell-side analysts forecast that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at $4,305,000. The trade was a 1.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 32,535 shares of company stock worth $219,580 over the last ninety days. Corporate insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On Gyre Therapeutics

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its holdings in shares of Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after acquiring an additional 14,365 shares during the period. Bank of New York Mellon Corp grew its position in Gyre Therapeutics by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after buying an additional 1,941 shares during the last quarter. Barclays PLC grew its position in Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after buying an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after buying an additional 45,772 shares during the last quarter. Finally, State Street Corp grew its position in Gyre Therapeutics by 10.7% in the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after buying an additional 19,472 shares during the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.